IP Library › Granted Patent US 10,307,405
Granted Patent B2
US 10,307,405 · App. 14/779,045 · Granted Jun 4, 2019

Stable veterinary combination formulations of macrocyclic lactones and imidazothiazoles

Inventors: Guy Francis de Rose (Kalamazoo, MI); Sachin Pundlik Kolhe (Mumbai, IN)
Assignee: Zoetis Services LLC
A61K31/429A61K9/0017A61K9/0019A61K31/365A61K31/415A61K31/4184A61K31/7048A61K45/00A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,307,405
App. No.
14/779,045
Granted
Jun 4, 2019
Kind
B2
Abstract

The present invention is directed to stabilized compositions comprising at least one macrocyclic lactone, or derivative thereof, in combination with levamisole, and an amino sugar stabilizing agent, optionally an additional antiparasitic agent, and a method for treating or controlling a parasitic infection or infestation in an animal by administering said composition.

Claims (26)

1. A stable injectable veterinary antiparasitic composition comprising:

(a) a therapeutically effective amount of doramectin, wherein the doramectin is present in the composition in the amount of about 0.1% w/w to about 1% w/w;

(b) a therapeutically effective amount of levamisole, or a pharmaceutically or veterinarily acceptable salt thereof, wherein the levamisole is present in the composition in the amount of about 4% w/w to about 24% w/w;

(c) an amino sugar stability enhancer consisting of meglumine; and

(d) at least one pharmaceutically or veterinarily acceptable carrier selected from the group consisting of benzyl alcohol, glycerol formal, triethylene glycol, and mixture thereof, and further comprising butylated hydroxyanisole, butylated hydroxytoluene, or mixture thereof.

2. The composition of claim 1 , wherein the meglumine is present in the composition in the amount of about 0.01% w/w to about 0.2% w/w.

3. The composition of claim 1 , wherein the levamisole is levamisole hydrochloride.

4. The composition of claim 1 wherein the at least one pharmaceutically or veterinarily acceptable carrier is selected from benzyl alcohol, triethylene glycol, or mixture thereof.

5. The composition of claim 1 wherein the at least one pharmaceutically or veterinarily acceptable carrier is glycerol formal.

6. A stable injectable veterinary antiparasitic composition comprising:

(a) a therapeutically effective amount of doramectin present in the composition in the amount of about 0.1% w/w to about 1% w/w;

(b) a therapeutically effective amount of levamisole, or a pharmaceutically acceptable salt thereof, present in the composition in the amount of about 4.0% w/w to about 24% w/w;

(c) an amino sugar stability enhancer consisting of meglumine, present in the composition in the amount of about 0.01% w/w to about 0.2% w/w; and

(d) at least one pharmaceutically or veterinarily acceptable carrier selected from the group consisting of benzyl alcohol, glycerol formal, triethylene glycol, and mixture thereof, and further comprising butylated hydroxyanisole, butylated hydroxytoluene, or mixture thereof.

7. The composition of claim 6 wherein the at least one pharmaceutically acceptable carrier is selected from benzyl alcohol, triethylene glycol, or mixture thereof.

8. The composition of claim 6 wherein the at least one pharmaceutically or veterinarily acceptable carrier is glycerol formal.

9. A method for alleviating a parasitic infection in an animal, comprising administering to said animal in need thereof, a stable injectable composition comprising:

(a) a therapeutically effective amount of doramectin present in the composition in the amount of about 0.1% w/w to about 1% w/w;

(b) a therapeutically effective amount of levamisole, or a pharmaceutically acceptable salt thereof, present in the composition in the amount of about 4.0% w/w to about 24% w/w;

(c) an amino sugar stability enhancer consisting of meglumine; and

(d) at least one pharmaceutically or veterinarily acceptable carrier selected from the group consisting of benzyl alcohol, triethylene glycol, glycerol formal, and mixture thereof, and further comprising butylated hydroxyanisole, butylated hydroxytoluene, or mixture thereof.

10. The method of claim 9 wherein the meglumine is present in the composition in the amount of about 0.01% w/w to about 0.2% w/w.

11. The method of claim 10 wherein the at least one pharmaceutically or veterinarily acceptable carrier is selected from benzyl alcohol, triethylene glycol, or mixture thereof.

12. The method of claim 10 wherein the at least one pharmaceutically or veterinarily acceptable carrier is glycerol formal.

13. The method of claim 9 wherein the animal is cattle or sheep.

14. The method of claim 9 wherein the composition is administered to the animal by subcutaneous injection.

Continuity (2)
Provisional Application 61811138 · Apr 12, 2013
Related Publication 20160051524A1 · Feb 25, 2016
Cited By (1)
US 12,544,336